Verastem, Inc. VSTM
Set alert
At close · Nov 2
After hours · Nov 2, 4:01 PM ET
- YTD
- +24.22%
- 1 year
- +1.48%
- Open
- 9.60
- Prev close
- 9.75
- Mkt cap
- 1.17B
- Vol
- 2.11M
- Avg vol
- 3.30M
- EPS
- -2.45
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.50
- High
- 9.79
- Forward P/E
- -7.86
- Beta
- 0.46
- Short ratio
- 3.77
- Inst. own
- 82.94%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 8.16
- 200-d avg
- 6.17
- 1y target
- 17.11
1M chart
Events in this range
- Oct 8, 2026Rating: BTIG · Buy → Buy
- Oct 15, 2026Rating: BTIG · Buy → Buy
- Oct 15, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 15, 2026Rating: Jefferies · Buy → Buy
- Oct 16, 2026Rating: Mizuho · Outperform → Outperform
- Oct 19, 2026Rating: BTIG · Buy → Buy
Signals (9)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 8 hours ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
Key statistics
- Market cap
- 1.17B
- Enterprise value
- 830.97M
- Trailing P/E
- 0.00
- Forward P/E
- -7.86
- PEG ratio
- 0.00
- Price / sales
- 13.31
- Price / book
- 17.37
- EPS (TTM)
- -2.45
- Beta
- 0.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -231.59%
- Revenue (TTM)
- 87.53M
- Revenue growth
- 1775.40%
- Free cash flow
- -103.43M
- Total cash
- 136.35M
- Total debt
- 84.33M
- Return on equity
- -471.16%
- Shares outstanding
- 121.50M
- Short % of float
- 14.22%
- 50-day average
- 8.16
- 200-day average
- 6.17
Analyst view
Consensus: strong buy
- Target (low)
- 12.00
- Target (mean)
- 17.11
- Target (high)
- 24.00
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.44.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.47299 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.43049 | -0.35 | +0.08 | +18.70% |
| May 7, 2026 | Mar 31, 2026 | -0.46 | -0.37 | +0.09 | +19.57% |
| Mar 4, 2026 | Dec 31, 2025 | -0.49 | -0.39 | +0.10 | +20.41% |
| Nov 4, 2025 | Sep 30, 2025 | -0.51 | -1.35 | -0.84 | -164.71% |
| Aug 7, 2025 | Jun 30, 2025 | -0.85 | -0.39 | +0.46 | +54.12% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | BTIG | reit | Buy | Buy |
| Oct 16, 2026 | Mizuho | main | Outperform | Outperform |
| Oct 15, 2026 | Jefferies | main | Buy | Buy |
| Oct 15, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 15, 2026 | BTIG | main | Buy | Buy |
| Oct 8, 2026 | BTIG | reit | Buy | Buy |
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- verastem.com
News
- Verastem Oncology to Participate in Upcoming November Investor Conferences
- Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
- Mizuho Maintains Outperform on Verastem, Raises Price Target to $14
- Jefferies Maintains Buy on Verastem, Raises Price Target to $13
- RBC Capital Maintains Outperform on Verastem, Raises Price Target to $19
- Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
- BTIG Maintains Buy on Verastem, Raises Price Target to $24
- Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript
- Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III
- Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers
Your note
Sign in to keep a note on VSTM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY MICHAEL P | Director | Stock Award(Grant) | May 20, 2026 | 108,000 |
| CALKINS DANIEL | Chief Financial Officer | Sale | Sep 20, 2026 | 118,014 |
| JOHNSON JOHN H. | Director | Stock Award(Grant) | May 20, 2026 | 52,666 |
| KAPUR ANIL | Director | Stock Award(Grant) | May 20, 2026 | 52,666 |
| PATERSON DANIEL W | Chief Executive Officer | Sale | Aug 2, 2026 | 589,940 |
| ROBERTSON MICHELLE | Director | Stock Award(Grant) | May 20, 2026 | 52,666 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.15% | 9,192,447 | 88.16M | Jun 29, 2026 |
| Armistice Capital, LLC | 7.76% | 7,024,000 | 67.36M | Jun 29, 2026 |
| RTW Investments LP | 7.33% | 6,635,793 | 63.64M | Jun 29, 2026 |
| Deep Track Capital, Lp | 6.34% | 5,740,850 | 55.05M | Jun 29, 2026 |
| State Street Corporation | 5.67% | 5,133,859 | 49.23M | Jun 29, 2026 |
| Rosalind Advisors, Inc. | 4.40% | 3,986,509 | 38.23M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.10% | 2,811,948 | 26.97M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.48% | 2,247,213 | 21.55M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.36% | 2,139,362 | 20.52M | Sep 29, 2026 |
| Vanguard Explorer Fund | 1.54% | 1,397,172 | 13.40M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.06% | 960,598 | 9.21M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.96% | 872,784 | 8.37M | Jul 30, 2026 |